EASL Congress 2026 - Late-Breaking Poster
May 27, 2026 at 8:30 AM CEST
Session: Late Breaker Posters (LBP-036)
Abstract Title: Pemvidutide Treatment Led to Fibrosis Regression After 24 Weeks in Patients with MASH: Quantitative Digital Pathology Analysis from the Phase 2b IMPACT Trial
Speaker: Dr. Shaheen Tomah, Director, Clinical Development, Altimmune
